Supported by science
Omega-3 fatty acids EPA and DHA are investigated in clinical science for wide range of health conditions. Currently major therapeutic application of EPA and DHA is in CVD and refers to lowering plasma triglyceride levels. Backed by extensive scientific evidence, EPA and DHA provide vital support to heart health in pharmaceutical applications, lowering plasma triglycerides levels, decreasing resting heart rate, blood pressure and inflammation, and improving vascular function.
Clinical trials referring to DHA and EPA cover such conditions as rheumatoid arthritis, osteoporosis, stroke, traumatic brain injury, cognitive decline, Alzheimer’s disease, depression, attention deficit/hyperactivity disorder, macular degeneration, asthma, inflammatory bowel disease, colon/breast/prostate cancer, skin disorders, sarcopenia, post-surgical recovery and others.
Contact us to find out more about our broad spectrum of EPA and DHA ingredients.